MX2019014450A - Vacuna contra la enteritis necrotica en aves de corral. - Google Patents

Vacuna contra la enteritis necrotica en aves de corral.

Info

Publication number
MX2019014450A
MX2019014450A MX2019014450A MX2019014450A MX2019014450A MX 2019014450 A MX2019014450 A MX 2019014450A MX 2019014450 A MX2019014450 A MX 2019014450A MX 2019014450 A MX2019014450 A MX 2019014450A MX 2019014450 A MX2019014450 A MX 2019014450A
Authority
MX
Mexico
Prior art keywords
pilus
poultry
polypeptide
vaccine against
necrotic enteritis
Prior art date
Application number
MX2019014450A
Other languages
English (en)
Inventor
Gong Jianhua
Lepp Dion
Original Assignee
Her Majesty The Queen In Right Of Canada As Represented By The Mini Of Agriculture And Agri Food
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Her Majesty The Queen In Right Of Canada As Represented By The Mini Of Agriculture And Agri Food filed Critical Her Majesty The Queen In Right Of Canada As Represented By The Mini Of Agriculture And Agri Food
Publication of MX2019014450A publication Critical patent/MX2019014450A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/33—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Clostridium (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Un polipéptido inmunógeno seleccionado de un polipéptido de pilus de Clostridium perfringens aislado, una variante del polipéptido de pilus; un fragmento del polipéptido de pilus; y un fragmento de la variante, es útil para la preparación de una vacuna para el tratamiento o prevención de la necrosis entérica en aves de corral. El polipéptido de pilus de Clostridium perfringens aislado incluye un pilus ensamblado o las subunidades pilus CnaA, FimA y/o FimB.
MX2019014450A 2017-05-31 2018-05-31 Vacuna contra la enteritis necrotica en aves de corral. MX2019014450A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762513001P 2017-05-31 2017-05-31
PCT/CA2018/050643 WO2018218360A1 (en) 2017-05-31 2018-05-31 Vaccine against necrotic enteritis in poultry

Publications (1)

Publication Number Publication Date
MX2019014450A true MX2019014450A (es) 2020-02-10

Family

ID=64454163

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019014450A MX2019014450A (es) 2017-05-31 2018-05-31 Vacuna contra la enteritis necrotica en aves de corral.

Country Status (8)

Country Link
US (2) US11318194B2 (es)
EP (1) EP3630800A4 (es)
JP (2) JP2020527051A (es)
CN (1) CN110691787A (es)
BR (1) BR112019025019A2 (es)
CA (1) CA3064461A1 (es)
MX (1) MX2019014450A (es)
WO (1) WO2018218360A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113234130A (zh) * 2021-05-24 2021-08-10 安徽医科大学第四附属医院 一种卡氏肺孢子菌重组蛋白及其制备方法与应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0985039B1 (en) * 1997-06-12 2008-02-20 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
CA2373534A1 (en) * 1999-07-13 2001-01-18 Medimmune, Inc. Donor strand complemented pilin and adhesin broad-based vaccines
MY149604A (en) * 2005-04-18 2013-09-13 Schering Plough Ltd C.perfringens alpha toxoid vaccine
CA2642721A1 (en) * 2006-02-17 2007-10-18 Novartis Ag Purification of bacterial antigens
CA2667255A1 (en) * 2006-10-27 2008-05-08 Dow Agrosciences Llc Poultry vaccine, for necrotic enteritis, comprising a mutated clostridium perfringens alpha toxin antigen, and methods of producing the vaccine
CA2669765A1 (en) * 2006-11-20 2008-05-29 Intervet International B.V. Use of clostridium perfringens type c bacterium for the manufacture of a vaccine
CN101848929A (zh) * 2007-05-25 2010-09-29 诺华有限公司 肺炎链球菌菌毛抗原
HUE025717T2 (en) * 2007-06-08 2016-04-28 Australian Poultry Crc Pty Ltd Clostridium NetB toxin
WO2009000066A1 (en) * 2007-06-22 2008-12-31 University Of Guelph Vaccine against clostridium perfringens
WO2011113801A1 (en) 2010-03-16 2011-09-22 Universiteit Gent Use of clostridium perfringens strain 23 to protect against necrotic enteritis
AR099470A1 (es) * 2014-02-17 2016-07-27 Intervet Int Bv Vacunas de virus de aves de corral líquidas
WO2020035741A2 (en) * 2018-07-05 2020-02-20 Novobind Livestock Therapeutics Inc. Antibodies against disease causing agents of poultry and uses thereof

Also Published As

Publication number Publication date
CA3064461A1 (en) 2018-12-06
CN110691787A (zh) 2020-01-14
RU2019137515A3 (es) 2021-12-03
JP2020527051A (ja) 2020-09-03
EP3630800A4 (en) 2021-03-24
RU2019137515A (ru) 2021-06-30
BR112019025019A2 (pt) 2020-06-30
US20220226455A1 (en) 2022-07-21
WO2018218360A1 (en) 2018-12-06
EP3630800A1 (en) 2020-04-08
JP2023090702A (ja) 2023-06-29
US20200093913A1 (en) 2020-03-26
US11318194B2 (en) 2022-05-03

Similar Documents

Publication Publication Date Title
PH12020500080A1 (en) Senecavirus a immunogenic compositions and methods thereof
EA201691993A1 (ru) Вакцина к вирусу эпидемической диареи свиней
TW201612316A (en) Porcine pseudorabies virus gene deletion strain, vaccine composition, and preparation method and application of vaccine composition
BR112016028816A2 (pt) combinação imunogênica, método para obter uma resposta imunológica específica, uso de uma combinação imunogênica, regime de vacinação para prevenção, redução ou tratamento de infecção por vírus sincicial respiratório, e, kit.
BR112017008165A2 (pt) anticorpos de domínio único direcionados contra antígenos intracelulares
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
PH12021550542A1 (en) Multivalent pneumococcal vaccines
MX2021009105A (es) Toxinas apxia, apxiia y apxiiia inactivadas.
MX2018006416A (es) Metodos para el tratamiento, prevencion y diagnostico de infeccion por el virus de la diarrea epidemica porcina.
MX2022003658A (es) Vacunas contra el virus de la hepatitis b (vhb) y metodos para tratar el vhb.
MX2018008529A (es) Virus de la tilapia de tipo ortomixo.
MX2018015506A (es) Vacuna contra virus de bronquitis infecciosa.
MY179251A (en) Methods and compositions for recombinant dengue viruses for vaccine and diagnostic development
PH12020552222A1 (en) Immunodominant proteins and fragments in multiple sclerosis
MX2020005555A (es) Construcciones inmunogenicas de peptidos de tau.
WO2018138681A9 (en) Hemagglutinin-specific antibodies and uses thereof
WO2018136698A3 (en) Bone-targeting antibodies
EA201892003A1 (ru) Лечение атопического дерматита собак
MX2019014450A (es) Vacuna contra la enteritis necrotica en aves de corral.
WO2018136779A3 (en) OXALOBACTER FORMIGENES(Of)-DERIVED FACTORS FOR THE TREATMENT OF TREATMENT/PREVENTION OF EXCESS OXALATE LEVELS
PH12021550441A1 (en) Modified pedv spike protein
MX2019000725A (es) Composiciones de vacuna para tratamiento de virus zika.
WO2016011432A3 (en) Identification of immunogenic mhc class ii peptides for immune-based therapy
WO2019028396A8 (en) Induction of protective immunity against antigens
BR112018072592A2 (pt) vetor de vacina de levedura que inclui polipeptídeos imunoestimulantes e antigênicos, e métodos de uso dos mesmos